NewsBenzingaDaxor kündigt neue klinische Studien an, die die BVA-Technologie in Hochrisiko-Herzinsuffizienzpopulationen validieren, um die Versorgung auf dem HFSA-Jahreskongress 2026 zu verbessern Daxor kündigt neue klinische Studien an, die die BVA-Technologie in Hochrisiko-Herzinsuffizienzpopulationen validieren, um die Versorgung auf dem HFSA-Jahreskongress 2026 zu verbessern Benzinga 2026.10.14 12:08 (GMT+0) Open on Benzinga Other news RBC Capital Maintains Sector Perform on Thermo Fisher Scientific, Raises Price Target to $730 First Industrial Realty Q3 2026 Earnings Call Transcript Warren Buffett Who? Berkshire Stock Hits Records as These Holdings Drive Gains Under Greg Abel Texas Attorney General Ken Paxton Secures Settlement With Lululemon To Enforce Chemical Safety Standards And Protect Consumers From Harmful Chemicals In Activewear Meta’s $25 Billion Headache: The ETF Cashing In on META’s Pain Here's How Much $1000 Invested In CACI International 15 Years Ago Would Be Worth Today
Texas Attorney General Ken Paxton Secures Settlement With Lululemon To Enforce Chemical Safety Standards And Protect Consumers From Harmful Chemicals In Activewear
